Australia - angielski - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - fentanyl citrate, quantity: 0.157 mg - injection, solution - excipient ingredients: sodium hydroxide; sodium chloride; water for injections - fentanyl gh injection is indicated for: ,- analgesic action of short duration during anaesthetic periods, premedication, induction and maintenance, and in the immediate post-operative period (recovery room) as the need arises; ,- use as an opioid analgesic supplement in general and regional anaesthesia; ,- administration with a neuroleptic such as droperidol injection as an anaesthetic premedication, for the induction of anaesthesia, and as an adjunct in the maintenance of general and regional anaesthesia.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - fentanyl citrate, quantity: 0.785 mg - injection, solution - excipient ingredients: sodium hydroxide; water for injections; sodium chloride - fentanyl gh injection is indicated for: ,- analgesic action of short duration during anaesthetic periods, premedication, induction and maintenance, and in the immediate post-operative period (recovery room) as the need arises; ,- use as an opioid analgesic supplement in general and regional anaesthesia; ,- administration with a neuroleptic such as droperidol injection as an anaesthetic premedication, for the induction of anaesthesia, and as an adjunct in the maintenance of general and regional anaesthesia.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - midazolam, quantity: 5 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; sodium chloride; sodium hydroxide; water for injections; nitrogen - iv as an agent for conscious sedation prior to short surgical, diagnostic, therapeutic or endoscopic procedures, such as bronchoscopy, gastroscopy, cystoscopy, coronary angiography and cardiac catheterisation, either alone or in conjunction with a narcotic; iv for induction of anaesthesia, preliminary to administration of other anaesthetic agents. with the use of a narcotic premedicant, induction of anaesthesia can be attained with a narrower dose range and in a shorter period of time. iv for sedation in intensive care units; intermittent administration or continuous infusion. im for preoperative sedation (induction of sleepiness or drowsiness and relief of apprehension) and to impair memory of perioperative events.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - midazolam, quantity: 5 mg/ml - injection, solution - excipient ingredients: nitrogen; hydrochloric acid; water for injections; sodium chloride; sodium hydroxide - iv as an agent for conscious sedation prior to short surgical, diagnostic, therapeutic or endoscopic procedures, such as bronchoscopy, gastroscopy, cystoscopy, coronary angiography and cardiac catheterisation, either alone or in conjunction with a narcotic; iv for induction of anaesthesia, preliminary to administration of other anaesthetic agents. with the use of a narcotic premedicant, induction of anaesthesia can be attained with a narrower dose range and in a shorter period of time. iv for sedation in intensive care units; intermittent administration or continuous infusion. im for preoperative sedation (induction of sleepiness or drowsiness and relief of apprehension) and to impair memory of perioperative events.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - midazolam, quantity: 1 mg/ml - injection, solution - excipient ingredients: nitrogen; hydrochloric acid; water for injections; sodium chloride; sodium hydroxide - iv as an agent for conscious sedation prior to short surgical, diagnostic, therapeutic or endoscopic procedures, such as bronchoscopy, gastroscopy, cystoscopy, coronary angiography and cardiac catheterisation, either alone or in conjunction with a narcotic; iv for induction of anaesthesia, preliminary to administration of other anaesthetic agents. with the use of a narcotic premedicant, induction of anaesthesia can be attained with a narrower dose range and in a shorter period of time. iv for sedation in intensive care units; intermittent administration or continuous infusion. im for preoperative sedation (induction of sleepiness or drowsiness and relief of apprehension) and to impair memory of perioperative events.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - midazolam, quantity: 5 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; sodium hydroxide; sodium chloride; water for injections; nitrogen - iv as an agent for conscious sedation prior to short surgical, diagnostic, therapeutic or endoscopic procedures, such as bronchoscopy, gastroscopy, cystoscopy, coronary angiography and cardiac catheterisation, either alone or in conjunction with a narcotic; iv for induction of anaesthesia, preliminary to administration of other anaesthetic agents. with the use of a narcotic premedicant, induction of anaesthesia can be attained with a narrower dose range and in a shorter period of time. iv for sedation in intensive care units; intermittent administration or continuous infusion. im for preoperative sedation (induction of sleepiness or drowsiness and relief of apprehension) and to impair memory of perioperative events.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - filgrastim, quantity: 600 microgram/ml - injection, solution - excipient ingredients: sodium hydroxide; polysorbate 80; water for injections; glutamic acid; sorbitol - indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs in doses not usually requiring bone marrow transplantation. ,indicated for reducing the duration of neutropenia and clinical sequelae in patients undergoing induction and consolidation chemotherapy for acute myeloid leukaemia. ,indicated for the mobilisation of autologous peripheral blood progenitor cells alone, or following myelosuppressive chemotherapy, in order to accelerate neutrophil and platelet recovery by infusion of such cells after myeloablative or myelosuppressive therapy in patients with non-myeloid malignancies. ,indicated for the mobilisation of peripheral blood progenitor cells, in normal volunteers, for use in allogeneic peripheral blood progenitor cell transplantation.,in patients receiving myeloablative chemotherapy, is indicated for reducing the duration of neutropenia and clinical sequelae following autologous or allogeneic bone marrow transplantation.,indicated for chronic administration to increase neutrophil counts and to reduce the incidence and duration of infections in patients with severe chronic neutropenia.,indicated in patients with hiv infection, for reversal of clinically significant neutropenia and subsequent maintenance of adequate neutrophil counts during treatment with antiviral and/or other myelosuppressive medications.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - filgrastim, quantity: 960 microgram/ml - injection, solution - excipient ingredients: sorbitol; polysorbate 80; sodium hydroxide; glutamic acid; water for injections - indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs in doses not usually requiring bone marrow transplantation. ,indicated for reducing the duration of neutropenia and clinical sequelae in patients undergoing induction and consolidation chemotherapy for acute myeloid leukaemia. ,indicated for the mobilisation of autologous peripheral blood progenitor cells alone, or following myelosuppressive chemotherapy, in order to accelerate neutrophil and platelet recovery by infusion of such cells after myeloablative or myelosuppressive therapy in patients with non-myeloid malignancies. ,indicated for the mobilisation of peripheral blood progenitor cells, in normal volunteers, for use in allogeneic peripheral blood progenitor cell transplantation.,in patients receiving myeloablative chemotherapy, is indicated for reducing the duration of neutropenia and clinical sequelae following autologous or allogeneic bone marrow transplantation.,indicated for chronic administration to increase neutrophil counts and to reduce the incidence and duration of infections in patients with severe chronic neutropenia.,indicated in patients with hiv infection, for reversal of clinically significant neutropenia and subsequent maintenance of adequate neutrophil counts during treatment with antiviral and/or other myelosuppressive medications.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

medsurge pharma pty ltd - alfentanil hydrochloride, quantity: 5.44 mg (equivalent: alfentanil, qty 5 mg) - injection, solution - excipient ingredients: water for injections; sodium hydroxide; sodium chloride - alfentanil injection is indicated for intravenous use by specialist anaesthetists and their trainees as:,? an analgesic supplement given by incremental intravenous boluses or continuous infusion; and,? an anaesthetic induction agent where in patients undergoing in-patient surgery, when endotracheal intubation and controlled ventilation are to be used.,because of its rapid onset and short duration of action, intravenous alfentanil (as hydrochloride) is particularly suited as a narcotic analgesic for short procedures and outpatients, provided that the patients are maintained under appropriate post-operative surveillance. however, intravenous alfentanil (as hydrochloride) is also useful as an analgesic supplement for procedures of medium to long duration, since periods of very painful stimuli can be easily overcome by administration of small increments of alfentanil (as hydrochloride) or by adapting the infusion rate.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

medsurge pharma pty ltd - alfentanil hydrochloride, quantity: 1.09 mg (equivalent: alfentanil, qty 1 mg) - injection, solution - excipient ingredients: sodium hydroxide; water for injections; sodium chloride - alfentanil injection is indicated for intravenous use by specialist anaesthetists and their trainees as:,? an analgesic supplement given by incremental intravenous boluses or continuous infusion; and,? an anaesthetic induction agent where in patients undergoing in-patient surgery, when endotracheal intubation and controlled ventilation are to be used.,because of its rapid onset and short duration of action, intravenous alfentanil (as hydrochloride) is particularly suited as a narcotic analgesic for short procedures and outpatients, provided that the patients are maintained under appropriate post-operative surveillance. however, intravenous alfentanil (as hydrochloride) is also useful as an analgesic supplement for procedures of medium to long duration, since periods of very painful stimuli can be easily overcome by administration of small increments of alfentanil (as hydrochloride) or by adapting the infusion rate.